Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?

Malignant melanoma still remains a cancer with very poor survival rates, although it is at the forefront of personalized medicine. Most patients show partial responses and disease progressed due to adaptative resistance mechanisms, preventing long-lasting clinical benefits to the current treatments....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesca Varrone, Luigi Mandrich, Emilia Caputo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	melanoma tumor microenvironment multicellular spheroids organotypic melanoma models skin-on-chip Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/720fcf7daf794e6ea90209ad5c6d7000
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:720fcf7daf794e6ea90209ad5c6d7000
record_format	dspace
spelling	oai:doaj.org-article:720fcf7daf794e6ea90209ad5c6d70002021-11-25T17:03:58ZMelanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?10.3390/cancers132257882072-6694https://doaj.org/article/720fcf7daf794e6ea90209ad5c6d70002021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5788https://doaj.org/toc/2072-6694Malignant melanoma still remains a cancer with very poor survival rates, although it is at the forefront of personalized medicine. Most patients show partial responses and disease progressed due to adaptative resistance mechanisms, preventing long-lasting clinical benefits to the current treatments. The response to therapies can be shaped by not only taking into account cancer cell heterogeneity and plasticity, but also by its structural context as well as the cellular component of the tumor microenvironment (TME). Here, we review the recent development in the field of immunotherapy and target-based therapy and how, in the era of tumor micro-tissue engineering, ex-vivo assays could help to enhance our melanoma biology knowledge in its complexity, translating it in the development of successful therapeutic strategies, as well as in the prediction of therapeutic benefits.Francesca VarroneLuigi MandrichEmilia CaputoMDPI AGarticlemelanomatumor microenvironmentmulticellular spheroidsorganotypic melanoma modelsskin-on-chipNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5788, p 5788 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	melanoma tumor microenvironment multicellular spheroids organotypic melanoma models skin-on-chip Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	melanoma tumor microenvironment multicellular spheroids organotypic melanoma models skin-on-chip Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Francesca Varrone Luigi Mandrich Emilia Caputo Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
description	Malignant melanoma still remains a cancer with very poor survival rates, although it is at the forefront of personalized medicine. Most patients show partial responses and disease progressed due to adaptative resistance mechanisms, preventing long-lasting clinical benefits to the current treatments. The response to therapies can be shaped by not only taking into account cancer cell heterogeneity and plasticity, but also by its structural context as well as the cellular component of the tumor microenvironment (TME). Here, we review the recent development in the field of immunotherapy and target-based therapy and how, in the era of tumor micro-tissue engineering, ex-vivo assays could help to enhance our melanoma biology knowledge in its complexity, translating it in the development of successful therapeutic strategies, as well as in the prediction of therapeutic benefits.
format	article
author	Francesca Varrone Luigi Mandrich Emilia Caputo
author_facet	Francesca Varrone Luigi Mandrich Emilia Caputo
author_sort	Francesca Varrone
title	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
title_short	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
title_full	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
title_fullStr	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
title_full_unstemmed	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
title_sort	melanoma immunotherapy and precision medicine in the era of tumor micro-tissue engineering: where are we now and where are we going?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/720fcf7daf794e6ea90209ad5c6d7000
work_keys_str_mv	AT francescavarrone melanomaimmunotherapyandprecisionmedicineintheeraoftumormicrotissueengineeringwherearewenowandwherearewegoing AT luigimandrich melanomaimmunotherapyandprecisionmedicineintheeraoftumormicrotissueengineeringwherearewenowandwherearewegoing AT emiliacaputo melanomaimmunotherapyandprecisionmedicineintheeraoftumormicrotissueengineeringwherearewenowandwherearewegoing
_version_	1718412782356922368

Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?

Ejemplares similares